公开(公告)号：US20180193346A1

公开(公告)日：2018-07-12

申请号：US15914479

申请日：2018-03-07

Applicant: Novartis AG

Inventor： Stephane Ferretti ,  Sebastien Jeay ,  Ensar Halilovic ,  Fang Li ,  Hui-Qin Wang

IPC: A61K31/519 ,  A61K31/506 ,  A61K31/496

CPC classification number: A61K31/519 ,  A61K31/4188 ,  A61K31/496 ,  A61K31/505 ,  A61K31/506 ,  A61K2300/00

Abstract: The disclosure relates to a pharmaceutical combination of a mdm2/4 inhibitor, namely (S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one or (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one, and a cyclin dependent kinase 4/6 (CDK4/6) inhibitor 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide. In addition, the disclosure relates to a pharmaceutical combination product. The disclosure also relates to corresponding pharmaceutical formulations, uses and treatment methods comprising said mdm2/4 inhibitor or a cyclin dependent kinase 4/6 (CDK4/6) inhibitor.

公开(公告)号：US12053470B2

公开(公告)日：2024-08-06

申请号：US17714996

申请日：2022-04-06

Applicant: Novartis AG ,  The General Hospital Corporation

Inventor： Leila Dardaei Alghalandis ,  Jeffrey Adam Engelman ,  Huaixiang Hao ,  Matthew J. Lamarche ,  Fang Li ,  Hui-Qin Wang

IPC: A61K31/506 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5377 ,  A61P35/00

CPC classification number: A61K31/506 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5377 ,  A61P35/00

Abstract: A pharmaceutical combination comprising an ALK inhibitor, in free form or a pharmaceutically acceptable salt thereof, and a SHP2 inhibitor, in free form or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

公开(公告)号：US20190350935A1

公开(公告)日：2019-11-21

申请号：US16526027

申请日：2019-07-30

Applicant: Novartis AG

Inventor： Giordano Caponigro ,  XIZHONG Huang ,  Joseph Lehar ,  Hui-Qin Wang

IPC: A61K31/53 ,  A61K31/5377 ,  A61K31/496 ,  A61K31/4745 ,  A61K45/06 ,  A61K31/4545 ,  A61K31/4439 ,  A61K31/427 ,  A61K31/4709

Abstract: The present invention relates to a pharmaceutical combination which comprises (a) a phosphatidylinositol 3-kinase inhibitor or pharmaceutically acceptable salt thereof, and (b) at least one c-Met receptor tyrosine kinase inhibitor or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly a c-Met dependent proliferative disease; a pharmaceutical composition comprising such combination; a method of treating a subject having a proliferative disease comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of proliferative disease; and a commercial package comprising such combination.

公开(公告)号：US20190083500A1

公开(公告)日：2019-03-21

申请号：US16157333

申请日：2018-10-11

Applicant: Novartis AG

Inventor： Giordano Caponigro ,  Xizhong Huang ,  Joseph Lehar ,  Hui-Qin Wang

IPC: A61K31/53 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4745 ,  A61K45/06 ,  A61K31/5377 ,  A61K31/496

Abstract: The present invention relates to a pharmaceutical combination which comprises (a) a phosphatidylinositol 3-kinase inhibitor or pharmaceutically acceptable salt thereof, and (b) at least one c-Met receptor tyrosine kinase inhibitor or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly a c-Met dependent proliferative disease; a pharmaceutical composition comprising such combination; a method of treating a subject having a proliferative disease comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of proliferative disease; and a commercial package comprising such combination.

公开(公告)号：US20170157134A1

公开(公告)日：2017-06-08

申请号：US15433392

申请日：2017-02-15

Applicant: Novartis AG

Inventor： Qing Sheng ,  Hui-Qin Wang ,  Fang Li ,  Jinsheng Liang ,  Zhu Alexander Cao ,  John Monahan ,  Richard Versace

IPC: A61K31/5355 ,  A61K31/506

CPC classification number: A61K31/5355 ,  A61K31/365 ,  A61K31/395 ,  A61K31/416 ,  A61K31/506 ,  A61K31/519 ,  A61K31/52 ,  A61K31/5377 ,  A61K45/06 ,  A61K2300/00

Abstract: A pharmaceutical combination comprising (a) a compound of formula (I), or pharmaceutically acceptable salts thereof; and (b) one or more at least one compound targeting, decreasing or inhibiting the intrinsic ATPase activity of Hsp90 and/or degrading, targeting, decreasing or inhibiting the Hsp90 client proteins via the ubiquitin proteosome pathway; the uses of such combination in the treatment or prevention of proliferative diseases; and methods of treating a subject suffering.

公开(公告)号：US20140275089A1

公开(公告)日：2014-09-18

申请号：US14350577

申请日：2012-10-11

Applicant: NOVARTIS AG

Inventor： Xizhong Huang ,  Cornelia Quadt ,  Hui-Qin Wang ,  Christine Fritsch ,  Christian René Schnell

IPC: A61K31/5377 ,  A61K31/4439

CPC classification number: A61K31/5377 ,  A61K31/16 ,  A61K31/235 ,  A61K31/428 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/506 ,  A61K31/519 ,  A61K31/52 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to a pharmaceutical combination comprising a 2-carboxamide cycloamino urea derivative compound of formula (I) and inhibitors of Heat Shock Protein 90, and the uses of such combinations in the treatment of proliferative diseases, more specifically PI3K dependent diseases, more specifically PI3K-alpha dependent diseases.

Abstract translation: 本发明涉及包含式（I）的2-甲酰胺环氨基脲衍生物化合物和热休克蛋白90抑制剂的药物组合，以及这些组合在治疗增殖性疾病中的用途，更具体地说是PI3K依赖性疾病 特别是PI3K-α依赖性疾病。

公开(公告)号：US20200253980A1

公开(公告)日：2020-08-13

申请号：US16820886

申请日：2020-03-17

Applicant: Novartis AG

Inventor： Giordano Caponigro ,  XIZHONG Huang ,  Joseph Lehar ,  Hui-Qin Wang

IPC: A61K31/53 ,  A61K45/06 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/5377

Abstract: The present invention relates to a pharmaceutical combination which comprises (a) a phosphatidylinositol 3-kinase inhibitor or pharmaceutically acceptable salt thereof, and (b) at least one c-Met receptor tyrosine kinase inhibitor or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly a c-Met dependent proliferative disease; a pharmaceutical composition comprising such combination; a method of treating a subject having a proliferative disease comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of proliferative disease; and a commercial package comprising such combination.

公开(公告)号：US20190160069A1

公开(公告)日：2019-05-30

申请号：US16263517

申请日：2019-01-31

Applicant: Novartis AG

Inventor： Stephane Ferretti ,  Sebastien Jeay ,  Ensar Halilovic ,  Fang Li ,  Hui-Qin Wang

IPC: A61K31/519 ,  A61K31/506 ,  A61K31/4188 ,  A61K31/505 ,  A61K31/496

Abstract: The disclosure relates to a pharmaceutical combination of a mdm2/4 inhibitor, namely (S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one or (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one, and a cyclin dependent kinase 4/6 (CDK4/6) inhibitor 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide. In addition, the disclosure relates to a pharmaceutical combination product. The disclosure also relates to corresponding pharmaceutical formulations, uses and treatment methods comprising said mdm2/4 inhibitor or a cyclin dependent kinase 4/6 (CDK4/6) inhibitor.

公开(公告)号：US20180185365A1

公开(公告)日：2018-07-05

申请号：US15879942

申请日：2018-01-25

Applicant: Novartis AG

Inventor： Fang LI ,  Hui-Qin Wang ,  Ensar Halilovic ,  Jinsheng Liang

IPC: A61K31/506 ,  A61K31/496 ,  A61K31/435 ,  A61K31/404 ,  A61K31/4025 ,  A61K45/06

CPC classification number: A61K31/506 ,  A61K31/4025 ,  A61K31/404 ,  A61K31/435 ,  A61K31/496 ,  A61K45/06 ,  A61K2300/00

Abstract: A pharmaceutical combination comprising (a) an ALK inhibitor, or a pharmaceutically acceptable salt thereof, and (b) at least one HDMA-2/p53 receptor inhibitor or a pharmaceutically acceptable salt, or at least one BRaf inhibitor or a pharmaceutically acceptable salt, and optionally a pharmaceutically acceptable carrier, for simultaneous, separate or sequential administration; the uses of such combination in the treatment of cancer; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

公开(公告)号：US20170143723A1

公开(公告)日：2017-05-25

申请号：US15423855

申请日：2017-02-03

Applicant: Novartis AG

Inventor： Stephane Ferretti ,  Sebastien Jeay ,  Ensar Halilovic ,  Fang LI ,  Hui-Qin Wang

IPC: A61K31/519 ,  A61K31/496 ,  A61K31/506

CPC classification number: A61K31/519 ,  A61K31/4188 ,  A61K31/496 ,  A61K31/505 ,  A61K31/506 ,  A61K2300/00

Abstract: The disclosure relates to a pharmaceutical combination of a mdm2/4 inhibitor, namely (S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one or (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one, and a cyclin dependent kinase 4/6 (CDK4/6) inhibitor 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide. In addition, the disclosure relates to a pharmaceutical combination product. The disclosure also relates to corresponding pharmaceutical formulations, uses and treatment methods comprising said mdm2/4 inhibitor or a cyclin dependent kinase 4/6 (CDK4/6) inhibitor.